Larimar Therapeutics announce plans for phase 3 trial of Nomlabofusp for FA
On March 24th 2025, the pharmaceutical company Larimar Therapeutics announced their plans to start conducting a phase 3 trial of their Friedreich’s ataxia (FA) drug Nomlabofusp in mid-2025. This follows […]
Larimar Therapeutics announce plans for phase 3 trial of Nomlabofusp for FA Read More »
